Skip to main content

Table 3 Comparing early treatment discontinuation, treatment failure, and hematological AEs between matched treatment groups after adjusting imbalanced baseline variables

From: Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study

Treatment comparison Platinum/Pemetrexed vs. Platinum/Docetaxel Platinum/Pemetrexed vs. Platinum/Paclitaxel Platinum/Pemetrexed vs. Platinum/Gemcitabine Platinum/Pemetrexed vs. Platinum/Vinorelbine
Sample size 190 236 398 144
Outcome measures OR 95% CI P value* OR 95% CI P value* OR 95% CI P value* OR 95% CI P value*
Lower limit Upper limit Lower limit Upper limit Lower limit Upper limit Lower limit Upper limit
Early treatment discontinuation 0.239 0.106 0.536 0.001 0.389 0.210 0.722 0.003 0.340 0.215 0.538 <0.001 0.250 0.096 0.654 0.005
Treatment failure 0.377 0.189 0.750 0.006 0.257 0.134 0.493 <0.001 0.381 0.241 0.601 <0.001 0.265 0.109 0.647 0.004
Hematological AE                 
Neutropenia 2.140 0.738 6.205 0.161 0.695 0.352 1.372 0.295 1.300 0.789 2.143 0.304 0.360 0.132 0.981 0.046
Leukopenia 2.028 0.691 5.948 0.198 0.687 0.351 1.345 0.273 0.633 0.392 1.023 0.062 0.423 0.165 1.082 0.073
Anemia 0.905 0.404 2.026 0.808 0.618 0.326 1.174 0.142 0.357 0.221 0.576 <0.001 0.181 0.046 0.710 0.014
Thrombocytopenia 0.790 0.287 2.178 0.649 0.581 0.287 1.174 0.130 0.345 0.209 0.570 <0.001 1.105 0.413 2.960 0.842
Any hematological AE 0.687 0.327 1.442 0.321 0.508 0.274 0.943 0.032 0.383 0.229 0.642 <0.001 0.332 0.092 1.200 0.093
  1. AE, adverse event; OR, odds ratio; CI, confidence interval. *: P values less than 0.05 were in bold to indicate significant differences.